Extended Data Fig. 5: Relationship between the binding affinity, neutralizing activity, and CVR entry-promoting efficiency of 25 SARS-CoV-2 RBD-targeting nanobody-fused receptors.
a, b, Assessment of the entry-promoting ability of 25 nanobody-CVRs in HEK293T cells, indicated by GFP (a) and the RLU (b), respectively. Data are presented as mean ± s.d. (n = 3 wells of independently infected cells), representative of two independent experiments. One-way ANOVA analysis followed by Dunnett’s test. Scale bars: 200 μm. c, Comparing RBD binding, neutralization, and PSV entry-promoting ability of different nanobody-fused proteins in HEK293T cells. RBD-mFc binding and PSV entry assays were conducted in HEK293T transiently expressing the 25 nanobody-CVRs. The SARS-CoV-2 PSV neutralization assay was performed in HEK293T-ACE2 in the presence of indicated nanobody-Fc recombinant proteins (10 μg ml−1). Data are representative results of two independent experiments with similar results and plotted by the mean (n = 3 wells of independently infected/bound cells). ***P < 0.001, ****P < 0.0001; NS, Not significant (P > 0.05).
